infertility (assisted reproductive technology)
Women's health · 2014–2016
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| follitropin alfa + lutropin alfa; lutropin alfa Stimulation of follicular development under the Section 100 IVF program. | Mar 2016 | Recommended | none received |
| triptorelin acetate Down-regulation and prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) as part of an… | Mar 2016 | Recommended with restriction | none received |
| follitropin alfa and lutropin alfa Stimulation of follicular development in women with severe LH and FSH deficiency for assisted reproductive technology (IVF/GIFT) treatment. | Mar 2015 | Recommended with restriction | input received ACCESS Australia · National Infertility Network |
| follitropin alfa and lutropin alfa Stimulation of follicular development in women with severe luteinising hormone (LH) and follicle stimulating hormone (FSH) deficiency who are receiving… | Mar 2014 | Not recommended | unclear |
Who spoke
ACCESS Australia · National Infertility Network
What the PBS pays
$256M in government benefit over 2024–25, across 189,367 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| follitropin alfa + lutropin alfa; lutropin alfa | $124.6M |
| follitropin alfa and lutropin alfa | $124.6M |
| triptorelin acetate | $6.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.